Dyne Therapeutics

DYNNASDAQ

FORCE targeted delivery platform for muscle diseases

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 177 days ago · archived: kept for reference, not maintained · where each field comes from

rare muscle diseaseoligonucleotide therapeutics

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for DYN yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

DYNE-101 Phase 3 DM1: Zeleciment basivarsen (DYNE-101) in Myotonic dystrophy type 1 — primary completion

2028-07

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

DYNE-251 Phase 3 DMD: Zeleciment rostudirsen (DYNE-251) in Duchenne muscular dystrophy, exon 51 — primary completion

2030-12

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

ACHIEVE: DYNE-101 in Myotonic dystrophy type 1 — primary completion

2029-07

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneModerate

Pipeline

DrugIndicationPhaseExpected data
DYNE-101myotonic dystrophy type 1Phase 2Not disclosed▼
DYNE-251Duchenne muscular dystrophy exon 51Phase 2Not disclosed▼

Analysis

We have not yet written an analysis of Dyne Therapeutics that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade DYN commission-free on Webullvia Webull · Affiliate

Comparable companies

Sarepta TherapeuticsAvidity BiosciencesPepGen

Sponsored

Get premium DYN analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Dyne Therapeutics has 4 Phase 2 or 3 studies on ClinicalTrials.gov: 4 ongoing.

0

Completed

0

Stopped early

4

Ongoing

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.